Fragment-based drug design (FBDD) has emerged as an efficient hit-identification and/or-optimization strategy with a higher hit rate than high-throughput screening (HTS). Whereas fragment linking is more challenging, fragment growing has become the preferred fragment-optimization strategy, requiring synthesis of derivatives and validation of their binding mode at each step of the optimization cycle. Dynamic combinatorial chemistry (DCC) is a powerful and efficient strategy to identify ligands for biological targets. Here, we have demonstrated that the novel combination of fragment-growing and DCC is a highly powerful strategy to grow a fragment into a more potent, non-covalent inhibitor of the aspartic protease endothiapepsin. We have desig...